We also showed distinct systemic cytokine signatures in gastric and esophageal cancers and their benign conditions, with cytokine panels consisting of IL-1β/IL-1ra/IL-6/RANTES or IL-1β/IL-6/IL-4/IL-13 holding promise as differential biomarkers in GC. This evidence concerns the gene IL6 and esophageal cancer.